Pub Date : 2026-01-08DOI: 10.1016/j.gore.2026.102029
Amar Zaidan , Kelly H Bruce , Mark R Hopkins , Steven I Robinson , Carl H Rose , Wendaline M VanBuren , Carrie L Langstraat
Background
Extrauterine adenosarcomas are rare gynecologic malignancies that can arise within foci of pelvic endometriosis. They are often hormone mediated and thus are challenging to treat during pregnancy.
Case presentation
We present the case of a hormone-receptor positive extrauterine adenosarcoma arising within a known focus of pelvic endometriosis diagnosed in the second trimester of pregnancy. The posterior pelvic mass involved and completely obstructed the colon. The patient desired pregnancy continuation and was managed with surgical intestinal diversion followed by serial surveillance with MRI imaging. Indicated primary preterm cesarean delivery was performed at 30 weeks gestation, after which she was treated with dual anti-estrogen therapy followed by definitive surgical resection. Fifteen months after surgery, she remains free from disease.
Conclusion
We review salient topics including malignant transformation of endometriosis, hormone therapy for adenosarcoma without sarcomatous overgrowth, and ethical considerations of cancer management during pregnancy.
{"title":"Active surveillance of an endometriosis-related, hormone-responsive pelvic adenosarcoma during pregnancy: A case report","authors":"Amar Zaidan , Kelly H Bruce , Mark R Hopkins , Steven I Robinson , Carl H Rose , Wendaline M VanBuren , Carrie L Langstraat","doi":"10.1016/j.gore.2026.102029","DOIUrl":"10.1016/j.gore.2026.102029","url":null,"abstract":"<div><h3>Background</h3><div>Extrauterine adenosarcomas are rare gynecologic malignancies that can arise within foci of pelvic endometriosis. They are often hormone mediated and thus are challenging to treat during pregnancy.</div></div><div><h3>Case presentation</h3><div>We present the case of a hormone-receptor positive extrauterine adenosarcoma arising within a known focus of pelvic endometriosis diagnosed in the second trimester of pregnancy. The posterior pelvic mass involved and completely obstructed the colon. The patient desired pregnancy continuation and was managed with surgical intestinal diversion followed by serial surveillance with MRI imaging. Indicated primary preterm cesarean delivery was performed at 30 weeks gestation, after which she was treated with dual anti-estrogen therapy followed by definitive surgical resection. Fifteen months after surgery, she remains free from disease.</div></div><div><h3>Conclusion</h3><div>We review salient topics including malignant transformation of endometriosis, hormone therapy for adenosarcoma without sarcomatous overgrowth, and ethical considerations of cancer management during pregnancy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102029"},"PeriodicalIF":1.3,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08DOI: 10.1016/j.gore.2026.102027
Olivia N. Julian , Anika Christofsen , Ramez N. Eskander
Background
The use of immune checkpoint inhibitors (ICI) has transformed the treatment of patients with advanced stage or recurrent mismatch repair deficient (dMMR) endometrial cancer. Importantly, however, ICI are commonly contraindicated in patients with preexisting autoimmune conditions. Immune related myasthenia gravis (irMG) is the second most common neurologic immune related adverse event (irAE) with ICIs, and there have been several case reports of ICI induced myasthenia gravis (MG) as well as cases of MG flares associated with ICI treatment.
Case Presentation
This case report describes the successful use of pembrolizumab in combination with carboplatin and paclitaxel and then continued as maintenance in a 70-year-old patient with recurrent dMMR endometrial cancer and myasthenia gravis. Utilizing a multidisciplinary treatment team, the patient received plasmapheresis every 3 weeks, preceding pembrolizumab infusion, without clinical evidence of MG symptom flare. The patient remains in clinical remission 8 months following completion of maintenance therapy.
Conclusion
Pembrolizumab was safely administered, without identifiable irAEs, and a robust clinical response in a patient with dMMR EC, where the clinical benefit of immunotherapy has been well established. Historically, patients with MG have been excluded from enrollment and treatment on clinical trials. Real world, pragmatic, clinical data may help inform expanded utilization beyond trial eligibility criteria.
{"title":"Successful use of immune checkpoint Inhibition in a patient with myasthenia gravis and recurrent endometrial cancer- expanding access beyond initial clinical trial eligibility","authors":"Olivia N. Julian , Anika Christofsen , Ramez N. Eskander","doi":"10.1016/j.gore.2026.102027","DOIUrl":"10.1016/j.gore.2026.102027","url":null,"abstract":"<div><h3>Background</h3><div> <!-->The use of immune checkpoint inhibitors<!--> <!-->(ICI)<!--> <!-->has transformed the treatment of patients with<!--> <!-->advanced stage or recurrent<!--> <!-->mismatch repair deficient (dMMR) endometrial cancer. Importantly, however,<!--> <!-->ICI<!--> <!-->are<!--> <!-->commonly contraindicated<!--> <!-->in patients with preexisting autoimmune conditions. Immune related myasthenia gravis (irMG) is the second most common neurologic<!--> <!-->immune related adverse event (irAE)<!--> <!-->with ICIs, and there have been several case reports of ICI induced myasthenia gravis (MG) as well as cases of MG flares associated with ICI treatment.</div></div><div><h3>Case Presentation</h3><div>This case report describes the successful use of pembrolizumab in combination with carboplatin and paclitaxel and then continued as maintenance in a 70-year-old patient with recurrent<!--> <!-->dMMR<!--> <!-->endometrial cancer and myasthenia gravis. Utilizing a multidisciplinary treatment team, the patient<!--> <!-->received<!--> <!-->plasmapheresis every 3 weeks, preceding pembrolizumab infusion, without clinical evidence of MG symptom flare. The patient<!--> <!-->remains<!--> <!-->in clinical<!--> <!-->remission<!--> <!-->8 months following completion of maintenance therapy.</div></div><div><h3>Conclusion</h3><div>Pembrolizumab was safely administered, without identifiable<!--> <!-->irAEs, and a robust clinical response in a patient with<!--> <!-->dMMR<!--> <!-->EC, where the clinical benefit of immunotherapy has been well established. Historically, patients with MG have been excluded from enrollment and treatment on clinical trials. Real<!--> <!-->world, pragmatic, clinical data may help inform expanded<!--> <!-->utilization<!--> <!-->beyond trial eligibility criteria.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102027"},"PeriodicalIF":1.3,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08DOI: 10.1016/j.gore.2026.102028
Chista R. Irani , Amelia Jernigan , Amma Agyemang , Tara Castellano
Introduction
Immunocompromised patients, such as those with systemic lupus erythematosus (SLE) and solid organ transplantation (SOT) are at increased risk for persistent high-risk human papilloma viral (HPV) infection and cervical cancer due to chronic immunosuppression.
Case
A 35-year-old woman with SLE and a right pelvic renal transplant was diagnosed with HPV16-positive cervical squamous cell carcinoma. Despite history of abnormal Pap smear, inconsistent screening led to a delayed diagnosis. She underwent surgical management first followed by chemoradiation. Surgical pathology confirmed FIGO Stage IIIC1 disease. With disease progression to pulmonary, hepatic and osseous sites, the patient was started on platinum-based chemotherapy with immune checkpoint inhibitors leading to acute kidney transplant rejection. She was transitioned to dialysis and continues palliative chemotherapy.
Conclusion
This case highlights the challenges of treating cervical cancer in an immunosuppressed renal-transplant recipient and emphasizes the importance of individualized screening and multidisciplinary care. Immunotherapy use in transplant patients warrants cautious consideration with thorough risk–benefit counseling.
{"title":"Considerations on management of advanced cervical squamous cell carcinoma in a solid organ transplant and immunocompromised patient: A case report","authors":"Chista R. Irani , Amelia Jernigan , Amma Agyemang , Tara Castellano","doi":"10.1016/j.gore.2026.102028","DOIUrl":"10.1016/j.gore.2026.102028","url":null,"abstract":"<div><h3>Introduction</h3><div>Immunocompromised patients, such as those with systemic lupus erythematosus (SLE) and solid organ transplantation (SOT) are at increased risk for persistent high-risk human papilloma viral (HPV) infection and cervical cancer due to chronic immunosuppression.</div></div><div><h3>Case</h3><div>A 35-year-old woman with SLE and a right pelvic renal transplant was diagnosed with HPV16-positive cervical squamous cell carcinoma. Despite history of abnormal Pap smear, inconsistent screening led to a delayed diagnosis. She underwent surgical management first followed by chemoradiation. Surgical pathology confirmed FIGO Stage IIIC1 disease. With disease progression to pulmonary, hepatic and osseous sites, the patient was started on platinum-based chemotherapy with immune checkpoint inhibitors leading to acute kidney transplant rejection. She was transitioned to dialysis and continues palliative chemotherapy.</div></div><div><h3>Conclusion</h3><div>This case highlights the challenges of treating cervical cancer in an immunosuppressed renal-transplant recipient and emphasizes the importance of individualized screening and multidisciplinary care. Immunotherapy use in transplant patients warrants cautious consideration with thorough risk–benefit counseling.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102028"},"PeriodicalIF":1.3,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08DOI: 10.1016/j.gore.2026.102025
Janhvi Sookram , Nisha Garg , Kevin B. Gilchrist
Background
The sertoliform variant of ovarian endometrioid carcinoma is exceedingly rare and often mimics sex-cord stromal or Brenner tumors, creating diagnostic challenges. Case: A 72-year-old woman presented with progressive abdominal distention and pain. MRI revealed a 22.7 × 13.8 × 16 cm mixed cystic–solid pelvic mass with mild ascites and elevated tumor markers. She underwent total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy. Pathology demonstrated low-grade endometrioid carcinoma, sertoliform variant, confined to the left ovary. Immunostains were positive for ER, AE1/AE3, β-catenin (nuclear/cytoplasmic), CDX2, and EMA. Molecular profiling revealed CTNNB1 (p.S33A) and FBXW7 (p.Q624*) pathogenic variants. She received adjuvant letrozole and remains disease-free at 3 years post-surgery. Conclusion: This case highlights the diagnostic complexity of ovarian tumors with sertoliform morphology and the importance of integrating morphologic, immunohistochemical, and molecular data. When confined to the ovary, prognosis is excellent following surgical resection. Endocrine therapy may be considered on an individualized basis in hormone-responsive tumors, although its role in early-stage disease remains unproven.
{"title":"Early-stage sertoliform endometrioid carcinoma of the ovary: diagnostic, molecular, and therapeutic considerations","authors":"Janhvi Sookram , Nisha Garg , Kevin B. Gilchrist","doi":"10.1016/j.gore.2026.102025","DOIUrl":"10.1016/j.gore.2026.102025","url":null,"abstract":"<div><h3>Background</h3><div>The sertoliform variant of ovarian endometrioid carcinoma is exceedingly rare and often mimics sex-cord stromal or Brenner tumors, creating diagnostic challenges. <strong>Case</strong><strong>:</strong> A 72-year-old woman presented with progressive abdominal distention and pain. MRI revealed a 22.7 × 13.8 × 16 cm mixed cystic–solid pelvic mass with mild ascites and elevated tumor markers. She underwent total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy. Pathology demonstrated low-grade endometrioid carcinoma, sertoliform variant, confined to the left ovary. Immunostains were positive for ER, AE1/AE3, β-catenin (nuclear/cytoplasmic), CDX2, and EMA. Molecular profiling revealed CTNNB1 (p.S33A) and FBXW7 (p.Q624*) pathogenic variants. She received adjuvant letrozole and remains disease-free at 3 years post-surgery. <strong>Conclusion</strong><strong>:</strong> This case highlights the diagnostic complexity of ovarian tumors with sertoliform morphology and the importance of integrating morphologic, immunohistochemical, and molecular data. When confined to the ovary, prognosis is excellent following surgical resection. Endocrine therapy may be considered on an individualized basis in hormone-responsive tumors, although its role in early-stage disease remains unproven.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102025"},"PeriodicalIF":1.3,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-07DOI: 10.1016/j.gore.2026.102021
Emily A. Miller , Amita Kulkarni , Jeff F. Lin , Evelyn Cantillo , Melissa K. Frey , Eloise Chapman-Davis , Higinia Cardenes , Kevin Holcomb
Background: While chemotherapy has largely replaced radiation therapy in upfront treatment of ovarian cancer, radiation has shown potential in the recurrent setting where chemoresistance, toxicities, and patient preferences may limit other treatment options. Hypofractionated radiation therapy (HFRT) is a highly conformal radiation therapy in which higher doses of radiation are delivered per treatment with the goal of fewer treatments. Objectives: To evaluate treatment response and survival for patients with recurrent ovarian cancer treated with HFRT and to evaluate treatment toxicity.
Methods: This was a retrospective cohort study of patients who received HFRT for the treatment of recurrent ovarian cancer at a single, large academic institution. Patient demographics, tumor characteristics, and treatment history details of the HFRT were collected via electronic medical record chart review. Outcomes including treatment response, survival and toxicity profile were analyzed. Treatment response was defined by RECIST 1.1 criteria. Toxicities were defined using the Radiation Therapy Oncology Group Criteria.
Results: 22 patients were reviewed. 1 patient (4.55%) had a complete response, 8 patients (36%) had a partial response, 7 patients (32%) had stable disease and 3 patients (14%) had progressive disease, and 3 patients (14%) were unevaluable by RECIST 1.1 criteria after treatment with HFRT. Mean progression free survival (PFS) was 11.5 months and overall survival (OS) was 28.7 months. HFRT was well-tolerated with no Grade 3 or 4 toxicities. The majority of patient’s had one to two lesions which were targeted for treatment.
Conclusions: For well-selected patients, particularly those with oligometastatic disease, HFRT should be considered as an additional treatment option for recurrent ovarian cancer.
{"title":"Hypofractionated short course radiation therapy for recurrent ovarian cancer","authors":"Emily A. Miller , Amita Kulkarni , Jeff F. Lin , Evelyn Cantillo , Melissa K. Frey , Eloise Chapman-Davis , Higinia Cardenes , Kevin Holcomb","doi":"10.1016/j.gore.2026.102021","DOIUrl":"10.1016/j.gore.2026.102021","url":null,"abstract":"<div><div>Background: While chemotherapy has largely replaced radiation therapy in upfront treatment of ovarian cancer, radiation has shown potential in the recurrent setting where chemoresistance, toxicities, and patient preferences may limit other treatment options. Hypofractionated radiation therapy (HFRT) is a highly conformal radiation therapy in which higher doses of radiation are delivered per treatment with the goal of fewer treatments. Objectives: To evaluate treatment response and survival for patients with recurrent ovarian cancer treated with HFRT and to evaluate treatment toxicity.</div><div>Methods: This was a retrospective cohort study of patients who received HFRT for the treatment of recurrent ovarian cancer at a single, large academic institution. Patient demographics, tumor characteristics, and treatment history details of the HFRT were collected via electronic medical record chart review. Outcomes including treatment response, survival and toxicity profile were analyzed. Treatment response was defined by RECIST 1.1 criteria. Toxicities were defined using the Radiation Therapy Oncology Group Criteria.</div><div>Results: 22 patients were reviewed. 1 patient (4.55%) had a complete response, 8 patients (36%) had a partial response, 7 patients (32%) had stable disease and 3 patients (14%) had progressive disease, and 3 patients (14%) were unevaluable by RECIST 1.1 criteria after treatment with HFRT. Mean progression free survival (PFS) was 11.5 months and overall survival (OS) was 28.7 months. HFRT was well-tolerated with no Grade 3 or 4 toxicities. The majority of patient’s had one to two lesions which were targeted for treatment.</div><div>Conclusions: For well-selected patients, particularly those with oligometastatic disease, HFRT should be considered as an additional treatment option for recurrent ovarian cancer.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102021"},"PeriodicalIF":1.3,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-07DOI: 10.1016/j.gore.2026.102026
Claudia Marie S. Watkins , Mojtaba Allahifard , Juan Cattoni , Lauren Montemorano
{"title":"Severe leukemoid reaction and spontaneous tumor lysis syndrome in a young patient with undifferentiated Lynch syndrome-associated ovarian cancer","authors":"Claudia Marie S. Watkins , Mojtaba Allahifard , Juan Cattoni , Lauren Montemorano","doi":"10.1016/j.gore.2026.102026","DOIUrl":"10.1016/j.gore.2026.102026","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102026"},"PeriodicalIF":1.3,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145920936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oncologically safe minimally invasive management of a 25 cm cystic abdominopelvic mass using contained, controlled drainage and removal","authors":"Yasmin Abozenah , Michelle Greenman , Ashley Goreshnik , Gary Altwerger","doi":"10.1016/j.gore.2025.102014","DOIUrl":"10.1016/j.gore.2025.102014","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102014"},"PeriodicalIF":1.3,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive soft tissue sarcoma characterized by a high risk of local recurrence. Vulvar involvement is exceedingly uncommon and often misdiagnosed as a bening lesion, resulting in delayed diagnosis. Complete surgical excision with negative margins is essential but can be challenging in anatomically sensitive areas as the vulva.
Case presentation
A 55-year-old Puerto Rican woman presented with a slowly enlarging lesion of the left labia majora that was initially managed as a furuncle. Progressive growth and symptoms prompted biopsy, which confirmed DFSP. Staging imaging revealed no metastatic disease. The patient underwent a single-stage left radical hemivulvectomy with immedate reconstruction using a V-Y fasciocutaneous advancement flap. Histopathologic examination demonstrated classic DFSP with uniform spindle cellls in a storiform pattern, stong diffuse CD34 positivity, and negative surgical margins. Postoperative recovery was uncomplicated, with excellent wound healing and flap viability.
Conclusion
This case emphasizes the importance of early biopsy of persistent vulvar lesions and highlights the role of multidiciplinary surgical planning. Single-stage radical excision with immediate reconstruction can achieve favorable oncologic and functional outcomes in vulvar DFSP. Long-term surveillance remains essential due to the potential for late local recurrence.
{"title":"Vulvar dermatofibrosarcoma protuberans in a 55-year-old female: A case report, surgical reconstruction approach and literature review","authors":"Amanda Detrés , Itzamar Pastrana , Marjolaine Suárez , Ricardo Gómez","doi":"10.1016/j.gore.2026.102024","DOIUrl":"10.1016/j.gore.2026.102024","url":null,"abstract":"<div><h3>Background</h3><div>Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive soft tissue sarcoma characterized by a high risk of local recurrence. Vulvar involvement is exceedingly uncommon and often misdiagnosed as a bening lesion, resulting in delayed diagnosis. Complete surgical excision with negative margins is essential but can be challenging in anatomically sensitive areas as the vulva.</div></div><div><h3>Case presentation</h3><div>A 55-year-old Puerto Rican woman presented with a slowly enlarging lesion of the left labia majora that was initially managed as a furuncle. Progressive growth and symptoms prompted biopsy, which confirmed DFSP. Staging imaging revealed no metastatic disease. The patient underwent a single-stage left radical hemivulvectomy with immedate reconstruction using a V-Y fasciocutaneous advancement flap. Histopathologic examination demonstrated classic DFSP with uniform spindle cellls in a storiform pattern, stong diffuse CD34 positivity, and negative surgical margins. Postoperative recovery was uncomplicated, with excellent wound healing and flap viability.</div></div><div><h3>Conclusion</h3><div>This case emphasizes the importance of early biopsy of persistent vulvar lesions and highlights the role of multidiciplinary surgical planning. Single-stage radical excision with immediate reconstruction can achieve favorable oncologic and functional outcomes in vulvar DFSP. Long-term surveillance remains essential due to the potential for late local recurrence.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102024"},"PeriodicalIF":1.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-30DOI: 10.1016/j.gore.2025.102018
Harriet Rothschild, Kelsey Keverline, Sara McKinney, Maureen Farrell, Minhazur Sarker
Objectives
Many reproductive-aged individuals use social media platforms to gather medical advice or find community. TikTok is one of the fastest growing social media platforms and used by many reproductive-aged individuals.
Methods
We evaluated the top 100 English-language videos on cervical cancer screening and dysplasia treatment for relevance to the hashtag and content quality and accuracy.
Results
Among the included videos, most of the content highlighted patients’ personal experiences and provided little medical educational value. Notably, the videos created by medical professionals were higher quality and more often contained accurate health information.
Conclusions
This study highlights the need to increase content quality on TikTok to raise awareness and uptake for cervical cancer screening and treatment in reproductive-aged individuals.
{"title":"From #cervicalcancerscreening to #LEEP – Quality and accuracy of cervical cancer content on TikTok","authors":"Harriet Rothschild, Kelsey Keverline, Sara McKinney, Maureen Farrell, Minhazur Sarker","doi":"10.1016/j.gore.2025.102018","DOIUrl":"10.1016/j.gore.2025.102018","url":null,"abstract":"<div><h3>Objectives</h3><div>Many reproductive-aged individuals use social media platforms to gather medical advice or find community. TikTok is one of the fastest growing social media platforms and used by many reproductive-aged individuals.</div></div><div><h3>Methods</h3><div>We evaluated the top 100 English-language videos on cervical cancer screening and dysplasia treatment for relevance to the hashtag and content quality and accuracy.</div></div><div><h3>Results</h3><div>Among the included videos, most of the content highlighted patients’ personal experiences and provided little medical educational value. Notably, the videos created by medical professionals were higher quality and more often contained accurate health information.</div></div><div><h3>Conclusions</h3><div>This study highlights the need to increase content quality on TikTok to raise awareness and uptake for cervical cancer screening and treatment in reproductive-aged individuals.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102018"},"PeriodicalIF":1.3,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号